https://www.selleckchem.com/pr....oducts/elafibranor.h
Assessment involves clinical examination, laboratory tests, echocardiography, electrocardiography, heart rhythm, cardiac function, and quality of life. The primary endpoint is a composite of all-cause mortality or re-admission due to worsening HF. include the assessments of cardiac remodelling, cardiac functional capacity, and quality of life. The SHIFT-AHF trial will shed further light on the role of early HR reduction using ivabradine in patients with AHF. The SHIFT-AHF trial will shed further light on the role of early HR reducti
Like
Comment
Share
